Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1709

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 1709
---
 6,127 Series A Warrants as a structuring fee. In March 2024, with the consent of the applicable investors,
a portion of the shares of Series A Preferred Stock and Series A Warrants transferred to the purchasers of Series B Preferred
Stock described below.

99

In March 2024, we issued
an aggregate of 626 shares of Series B Preferred Stock, at a price of $1,000 per share, initially convertible into 626 shares of Common
Stock at $1,000.00 per share, resulting in aggregate gross proceeds to us of approximately $0.5 million.

In May 2024, we issued 3,456
shares of Common Stock to an investor as commitment shares in consideration for entering into an equity line of credit with us. The issuance
of these securities was made pursuant to Section 4(a)(2) of the Securities Act, and the rules promulgated thereunder, to an accredited
investor.

In September 2024, we issued
an aggregate of 2,853 shares of Series C Preferred Stock, at a price of $1,000 per share, and 81,753 shares of Series C Warrants, resulting
in aggregate gross proceeds to us of approximately $1.25 million.

In December 2024, we issued warrants to purchase an aggregate of 84,061
shares of Common Stock, with an exercise price of $5.61 per share, which was the closing price of the Common Stock on Nasdaq on December
20, 2024 (as adjusted for the Reverse Stock Split), to certain institutional investors. Such shares were issued in reliance upon the exemption
from registration set forth in Section 4(a)(2) of the Securities Act.

The issuance of these securities
was made pursuant to 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and the rules promulgated thereunder, to accredited
investors.

Use of Proceeds from Registered Offerings

Not
applicable.

Purchases of Equity Securities by the Issuer
and Affiliated Purchasers

None.

Item 6. [RESERVED]

Item 7. Management’s Discussion and Analysis
of Financial Condition and Results of Operations of CERo.

The following discussion
and analysis of CERo’s financial condition and results of operations should be read in conjunction with our audited consolidated
financial statements and the notes related thereto which are included in Item 8 of this Annual Report